Cited by 155Inflammatory Biomarkers in Disease PrognosisCancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Eosinophilic Count as a Biomarker for Prognosis of Melanoma Patients and Its Importance in The Response to Immunotherapy

Moreira, Alvaro, Leisgang, Waltraud, Schuler, Gerold, Heinzerling, Lucie·2017·Immunotherapy

DOI 10.2217/imt-2016-0138

Open this paper in CoChat — free account

Abstract

AIM: The prognostic role of eosinophils in cancer has been controversial. Some entities such as gastrointestinal cancers show a better survival, while others such as Hodgkin's lymphoma a worse survival in patients with eosinophilia. Patients who exhibited an increase in eosinophils upon therapy with ipilimumab or pembrolizumab were shown to survive longer. We wanted to investigate whether eosinophilia is a prognostic marker in metastatic melanoma. METHODS: In total, 173 patients with metastatic melanoma from our data base (median age 60 years; n = 86 with immunotherapy, n = 87 without immunotherapy) were analyzed for eosinophil counts and survival over the course of 12 years. Eosinophilic count was detected by peripheral blood smear. The ethical committee had approved this retrospective study. RESULTS: Melanoma patients with eosinophilia at any point in their course of disease show a trend toward longer survival independently of their therapy. There is a statistically significant difference for the patients who survive at least 12 months (p < 0.005). In patients with checkpoint inhibitor therapy, survival was significantly prolonged in every patient with eosinophilia (p < 0.05). Furthermore, 69% of the patients treated with immunotherapy experienced at least once an eosinophilia of 5% or greater compared with 46% in the immunotherapy naive-group; for an eosinophilia of 10% values were 30 and 9%, respectively. Interestingly, in patients with more than 20% eosinophils (n = 7) survival was prolonged with a median of 35 months (range 19-60 months) as compared with 16 months (range 1-117 months). CONCLUSION: Eosinophilia is a prognostic marker in patients with metastatic melanoma.

Integrity signals

Registry

Crossref · 10.2217/imt-2016-0138

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., DAUD, A. I., Hodi, F. S., Hwu, W., Kefford, R. F., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,427
Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Brahmer, J. R., Drake, C. G., WOLLNER, I. S., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,967
Cancer regression and autoimmunity induced by cytotoxic t lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575
Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti–Cytotoxic T-Lymphocyte Antigen-4
Attia, P., Phan, G. Q., Maker, A. V., Robinson, M. R., Quezado, M. M., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.205 · Cited by 1,012
Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
Weide, B., Martens, A., Hassel, J. C., Berking, C., Postow, M. A., Bisschop, K., Simeone, E., Mangana, J., Schilling, B., Di Giacomo, A. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0127 · Cited by 589
Self-citation
Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8+ T cells
Carretero, R., Sektioglu, I. M., Garbi, N., Salgado, O. C., Beckhove, P., & Hämmerling, G. J. (2015) · Nature Immunology · doi:10.1038/ni.3159 · Cited by 501
Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab
Gebhardt, C., Sevko, A., Jiang, H., Lichtenberger, R., Reith, M., Tarnanidis, K., Holland-Letz, T., Umansky, L., Beckhove, P., Sucker, A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0676 · Cited by 367
Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival
Delyon, J., Mateus, C., Lefeuvre, D., Lanoy, E., Zitvogel, L., Chaput, N., Roy, S., Eggermont, A. M. M., Routier, E., & Robert, C. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt027 · Cited by 318
Identification of Innate IL-5–Producing Cells and Their Role in Lung Eosinophil Regulation and Antitumor Immunity
Ikutani, M., Yanagibashi, T., Ogasawara, M., Tsuneyama, K., Yamamoto, S., Hattori, Y., Kouro, T., Itakura, A., Nagai, Y., Τακακι, S., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1101270 · Cited by 314
Phase I Study of Adoptive T-Cell Therapy Using Antigen-Specific CD8+ T Cells for the Treatment of Patients With Metastatic Melanoma
Mackensen, A., Meidenbauer, N., Vogl, S., Laumer, M., Berger, J., & Andreesen, R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.1100 · Cited by 297

Show all 32 references

Sorted by citations

Items 101–155 of 155

The prognostic impact of peripheral blood eosinophil counts in metastatic renal cell carcinoma patients treated with nivolumab
Yoshimura, A., Nagahara, A., Ishizuya, Y., Yamamoto, Y., Hatano, K., Kawashima, A., Nakai, Y., Nakayama, M., Nishimura, K., Nonomura, N., et al. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01370-8 · Cited by 5
Identification of Precise Therapeutic Targets and Characteristic Prognostic Genes Based on Immune Gene Characteristics in Uveal Melanoma
Zhang, Z., Su, J., Li, L., & Du, W. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.666462 · Cited by 5
Immune Modulatory Effects of Radiotherapy
Frey, B., Rückert, M., & Gaipl, U. S. (2019) · Springer eBooks · doi:10.1007/978-3-319-52619-5_106-1 · Cited by 5
Exploring the Dynamics of Immune Checkpoint Inhibitor‐Induced Eosinophilia in Advanced/Metastatic Melanoma: A Comprehensive Retrospective Analysis
Diamantopoulos, P. T., Gkoufa, A., Anastasopoulou, A. N., Kouzis, P., Lyrarakis, G., Kyriakakis, G., & Gogas, H. J. (2025) · Cancer Medicine · doi:10.1002/cam4.70679 · Cited by 4
Absolute Increase in the Number and Proportion of Peripheral Eosinophils Associated With Immune Checkpoint Inhibitor Treatment in Non-small Cell Lung Cancer Patients
Osawa, H., Shiozawa, T., Okauchi, S., Sasatani, Y., Ohara, G., Sato, S., Miyazaki, K., Kodama, T., Kagohashi, K., Satoh, H., et al. (2021) · Cancer Diagnosis & Prognosis · doi:10.21873/cdp.10065 · Cited by 4
Eosinophil plays a crucial role in intestinal mucositis induced by antineoplastic chemotherapy
Arifa, R. D. D. N., de Brito, C. B., de Paula, T. P., Lima, R. L., Garcia, Z. M., Vieira, P. C., Boas, F. D. A. S. V., Queiroz‐Junior, C. M., da Silva, J. M., Silva, T. A., et al. (2021) · Immunology · doi:10.1111/imm.13442 · Cited by 4
LASSO logistic regression reveals a mixed MiRNA and serum-marker classifier for prediction of immunotherapy response in liquid biopsies of melanoma patients
Bender, M., Chen, I.-P., Bluhm, L., Mohr, P., Volkmer, B., & Greinert, R. (2024) · EJC Skin Cancer · doi:10.1016/j.ejcskn.2024.100260 · Cited by 3
Integrating neutrophils, lymphocytes and eosinophils: development and validation of the NLE Index in ICI-treated metastatic melanoma
Açar, F. P., Acar, C., Yüksel, H. Ç., Şahin, G., Bayir, B., Özdemir, I., Mermer, T., & Karaca, B. (2025) · Melanoma Research · doi:10.1097/cmr.0000000000001060 · Cited by 3
Inflammatory Infiltrates in Melanocytic Lesions
Relan, A., Desar, S., Dunnette, B., Shanley, R., & Giubellino, A. (2021) · International Journal of Morphology · doi:10.4067/s0717-95022021000200512 · Cited by 3
Severe eosinophilia and subsequent dermatologic immune‐related adverse event with squamous cell carcinoma antigen elevation induced by nivolumab and ipilimumab
Matsumoto, T., Kaneko, A., Kusakabe, Y., Nakayama, E., Tanaka, A., Yamamoto, N., Aihara, K., Yamaoka, S., & Mishima, M. (2022) · Respirology Case Reports · doi:10.1002/rcr2.1037 · Cited by 3
RETRACTED: The causal relationships of granulocytes and melanoma skin cancer: A univariable and multivariable Mendelian randomization study
Rui‐chang, Z., Hui‐zi, P., & Lin, Z. (2024) · Skin Research and Technology · doi:10.1111/srt.70007 · Cited by 2
Retracted
Prognostic Potential of Baseline Eosinophils at the Initiation of Immune Checkpoint Inhibitor Treatment of Metastatic Melanoma: A Systematic Review and Meta‐Analysis
Gambichler, T., Overbeck, J., Rached, N. A., Susok, L., & Weyer-Fahlbusch, S. S. (2025) · Journal of Skin Cancer · doi:10.1155/jskc/2561307 · Cited by 2
Eosinophils in solid cancers: sentinels, predictors, and therapeutic allies
Gilon, M., Boulet, D., Bours, V., Jérusalem, G., Josse, C., & Gennigens, C. (2026) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-026-03688-5 · Cited by 3
Association between blood eosinophil count and Duchenne muscular dystrophy severity and prognosis: a retrospective cohort study
Jiang, Z. D., Liao, H., Wu, L., Hu, W., Yang, L. M., Chen, B., Ning, Z., Tang, J., Xu, R., Chen, M., et al. (2023) · The Italian Journal of Pediatrics/Italian journal of pediatrics · doi:10.1186/s13052-023-01483-y · Cited by 2
Integrating Novel and Classical Prognostic Factors in Locally Advanced Cervical Cancer: A Machine Learning-Based Predictive Model (ESTHER Study)
Medici, F., Ferioli, M., Zamfir, A. A., Buwenge, M., Macchia, G., Deodato, F., Castellucci, P., Tagliaferri, L., Perrone, A. M., Iaco, P. D., et al. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15040153 · Cited by 2
ADCYAP1 as a pan-solid cancer biomarker: predictor of immunotherapy efficacy in bladder cancer and prognostic potential across solid tumors
Jing, X., & Deng, Y. (2025) · Discover Oncology · doi:10.1007/s12672-025-02408-3 · Cited by 3
Eosinophil dynamics during chemo-radiotherapy correlate to clinical outcome in stage Ⅱ-Ⅳa nasopharyngeal carcinoma patients: Results from a large cohort study
Li, D., Yang, L., Lin, J., Wu, Y., Tang, Z., Tu, H., Zhang, X., Liu, Y.-C., Yang, M., Wang, N.-H., et al. (2023) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2023.109900 · Cited by 1
Baseline and early changes in eosinophil count and neutrophil-to-eosinophil ratio predict outcomes in metastatic renal cell carcinoma treated with nivolumab
Fiala, O., Rejleková, K., Büchler, T., Študentová, H., Poprach, A., Vočka, M., Hošek, P., Kopecký, J., Matějů, M., Zemánková, A., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-32593-8 · Cited by 1
The Percentage of Peripheral Eosinophils as a Sensitive Marker for Differentiating FIGO Grade in Endometrial Adenocarcinomas
Akış, S., Öztürk, U. K., Keleş, E., Alınca, C. M., Apı, M., & Kabaca, C. (2022) · Journal of the Turkish-German Gynecological Association · doi:10.4274/jtgga.galenos.2022.2021.9-10 · Cited by 1
Chemotherapy Induced Eosinophilia and its Significance among the Cancer Patients Treated at a Tertiary Care Teaching Hospital, West Bengal
Ray, A., Pathak, S., Ghorai, S., Bhushan, B., Banerjee, S., & Ghosh, S. (2023) · Indian Journal of Public Health Research & Development · doi:10.37506/ijphrd.v14i3.19351 · Cited by 1
Developing and validating the model of tumor-infiltrating immune cell to predict survival in patients receiving radiation therapy for head and neck squamous cell carcinoma
Xu, T., Xu, M., Xu, Y.-Y., Cai, X.-J., Brenner, M. J., Twigg, J. A., Fei, Z.-D., & Chen, C.-B. (2024) · Translational Cancer Research · doi:10.21037/tcr-23-2345 · Cited by 2
A case of post-surgical inflammatory neuropathy with lower-extremity weakness after surgery for anorectal malignant melanoma that showed the effectiveness of immunotherapy
Asano, R., Kitazaki, Y., Ikawa, M., Kurebayasi, H., Koike, H., & Hamano, T. (2020) · Rinsho Shinkeigaku · doi:10.5692/clinicalneurol.cn-001441 · Cited by 1
Strongyloides—An uncommon cause of eosinophilia whilst on durvalumab
Quah, G. T., Blanchard, G., Miller, N. R., Wilson, P., & Nordman, I. I. C. (2022) · Cancer Reports · doi:10.1002/cnr2.1682
Patient with metastatic malignant melanoma treated with pembrolizumab
Fialová, A., & Arenbergerová, M. (2020) · Onkologie · doi:10.36290/xon.2020.036
Médecine de précision et immunoradiothérapie
Chargari, C., Robert, C., Genestie, C., & Deutsch, É. (2021) · Cancer/Radiothérapie · doi:10.1016/j.canrad.2021.06.032
Analysis of Regulatory T-cells-specific mRNAs for Improving Prognosis, Immunotherapy Response and Therapeutic Resistance of Patients With Prostate CancerPreprint
Ju, M., Fan, J., Zou, Y., Yu, M., Jiang, L., Wei, Q., Bi, J., Hu, B., Wang, L., Guan, Q., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-676662/v1
Improving immunotherapy responses in gastrointestinal cancers
Chalabi, M. (2022) · doi:10.33540/904
Relationship Between Peripheral Blood Eosinophil Count and the Severity and Prognosis of Children with Duchenne Muscular Dystrophy : A New Potentially Useful Predictor?Preprint
Jiang, Z. D., Liao, H., Wu, L., Hu, W., Yang, L. M., Chen, B., Ning, Z., Tang, J., Xu, R., Chen, M., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1383155/v1
Relationship between peripheral blood eosinophil count and the severity and prognosis of children with Duchenne Muscular Dystrophy : a new potentially useful predictor?Preprint
Jiang, Z. D., Liao, H., Wu, L., Hu, W., Yang, L. M., Chen, B., Ning, Z., Tang, J., Xu, R., Chen, M., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1383155/v2
The percentage of peripheral eosinophils as a sensitive marker for differentiating FIGO grade in endometrial adenocarcinomas
Akış, S., Öztürk, U. K., Keleş, E., Alınca, C. M., Apı, M., & Kabaca, C. (2022) · Journal of the Turkish-German Gynecological Association · doi:10.4274/jtgga.galenos.2022.2021-9-10
Der Biomarker „eosinophiles kationisches Protein“ (ECP)
Oremek, G. M., Passek, K., Braun, M., von der Eltz, V., & Dröge, J. (2022) · Zentralblatt für Arbeitsmedizin Arbeitsschutz und Ergonomie · doi:10.1007/s40664-022-00473-x
Strahlentherapie und Immuntherapie
Gaipl, U. S., Grosu, A., Frey, B., Rückert, M., Schäfer, H. S., & Popp, I. (2023) · Springer Reference Medizin · doi:10.1007/978-3-662-46764-0_177-1
Mendelian Randomization Analysis Shows that Elevated Eosinophil Cell Count Increases the Risk of Autoimmune Disorders but Protects Against Skin Cancer
Singh, A., & Akbari, P. (2022) · Journal of Student Research · doi:10.47611/jsrhs.v11i3.3026
Eosinophilia as a Predictive Biomarker for Melanoma Treatment, A Single Center Review
Reuben, D. Y. (2023) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2023.53.008338
Association between asthma and melanoma: Results from the NHANES 2009-2016 and Mendelian randomization studyPreprint
Tan, J., Huang, X., Dong, Y., & Li, J. (2024) · Research Square · doi:10.21203/rs.3.rs-4144117/v1
Additional file 7 of Dissecting immune cell stat regulation network reveals biomarkers to predict ICB therapy responders in melanoma
Wang, J., Li, F., Xu, Y., Zheng, X., Zhang, C., Hu, C., Xu, Y., Mi, W., Li, X., & Zhang, Y. (2021) · Figshare · doi:10.6084/m9.figshare.14936500
Additional file 5 of Dissecting immune cell stat regulation network reveals biomarkers to predict ICB therapy responders in melanoma
Wang, J., Li, F., Xu, Y., Zheng, X., Zhang, C., Hu, C., Xu, Y., Mi, W., Li, X., & Zhang, Y. (2021) · Figshare · doi:10.6084/m9.figshare.14936494
Additional file 2 of Dissecting immune cell stat regulation network reveals biomarkers to predict ICB therapy responders in melanoma
Wang, J., Li, F., Xu, Y., Zheng, X., Zhang, C., Hu, C., Xu, Y., Mi, W., Li, X., & Zhang, Y. (2021) · Figshare · doi:10.6084/m9.figshare.14936485
Additional file 8 of Dissecting immune cell stat regulation network reveals biomarkers to predict ICB therapy responders in melanoma
Wang, J., Li, F., Xu, Y., Zheng, X., Zhang, C., Hu, C., Xu, Y., Mi, W., Li, X., & Zhang, Y. (2021) · Figshare · doi:10.6084/m9.figshare.14936503
Additional file 6 of Dissecting immune cell stat regulation network reveals biomarkers to predict ICB therapy responders in melanoma
Wang, J., Li, F., Xu, Y., Zheng, X., Zhang, C., Hu, C., Xu, Y., Mi, W., Li, X., & Zhang, Y. (2021) · Figshare · doi:10.6084/m9.figshare.14936497
Additional file 4 of Dissecting immune cell stat regulation network reveals biomarkers to predict ICB therapy responders in melanoma
Wang, J., Li, F., Xu, Y., Zheng, X., Zhang, C., Hu, C., Xu, Y., Mi, W., Li, X., & Zhang, Y. (2021) · Figshare · doi:10.6084/m9.figshare.14936491
Additional file 3 of Dissecting immune cell stat regulation network reveals biomarkers to predict ICB therapy responders in melanoma
Wang, J., Li, F., Xu, Y., Zheng, X., Zhang, C., Hu, C., Xu, Y., Mi, W., Li, X., & Zhang, Y. (2021) · Figshare · doi:10.6084/m9.figshare.14936488
Additional file 1 of Dissecting immune cell stat regulation network reveals biomarkers to predict ICB therapy responders in melanoma
Wang, J., Li, F., Xu, Y., Zheng, X., Zhang, C., Hu, C., Xu, Y., Mi, W., Li, X., & Zhang, Y. (2021) · Figshare · doi:10.6084/m9.figshare.14936482
Utilizing non-histological serological markers in the prediction of recurrence and metastasis in head and neck melanoma
О., К. Л. (2024) · Oftalmologicheskii Zhurnal · doi:10.31288/oftalmolzh202435663
Methodological and conceptual considerations for examining the α-FAtE scoring in unresectable hepatocellular carcinoma
Akgüner, G. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010840
The predictive value of the neutrophil/eosinophil ratio in cancer patients undergoing immune checkpoint inhibition: a meta-analysis and a validation cohort in hepatocellular carcinoma
Xu, Y., Liu, Y., Han, H., He, Z., & Cao, W. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1633034
Additional file 1 of Nicotinamide inhibits melanoma in vitro and in vivo
Scatozza, F., Moschella, F., D’Arcangelo, D., Rossi, S., Tabolacci, C., Giampietri, C., Proietti, E., Facchiano, F., & Facchiano, A. (2020) · Figshare · doi:10.6084/m9.figshare.13064299
Additional file 9 of Dissecting immune cell stat regulation network reveals biomarkers to predict ICB therapy responders in melanoma
Wang, J., Li, F., Xu, Y., Zheng, X., Zhang, C., Hu, C., Xu, Y., Mi, W., Li, X., & Zhang, Y. (2021) · Figshare · doi:10.6084/m9.figshare.14936506
Additional file 2 of Nicotinamide inhibits melanoma in vitro and in vivo
Scatozza, F., Moschella, F., D’Arcangelo, D., Rossi, S., Tabolacci, C., Giampietri, C., Proietti, E., Facchiano, F., & Facchiano, A. (2020) · Figshare · doi:10.6084/m9.figshare.13064302
Tissue Injury and Biomaterial Treatment Modulate Tumor Growth and Response to ImmunotherapyPreprint
Ruta, A., Gray-Gaillard, E. F., Garcia, J. A., Huyer, L. D., Mathkour, Y., Cherry, C., Patatanian, M., Mejías, J. C., Maestas, D. R., Krishnan, K., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.02.703323
Multi-omics analysis identifies TLRscore for prognostic prediction and highlights TLR8 in macrophage-mediated antitumor immunity of lung adenocarcinoma
Li, A., Liu, J., Wu, H., Jin, Y., Zhang, H., Zhang, Z., Jiang, S., & Zhang, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1711401
Eosinophils: Effectors of Intraperitoneal Paclitaxel Antitumor Response
Senthil, M. (2026) · Annals of Surgical Oncology · doi:10.1245/s10434-026-19489-1
Baseline neutrophil-to-eosinophil ratio and neutrophil-to-lymphocyte ratio as prognostic markers in patients with unresectable biliary tract cancer treated with gemcitabine-cisplatin-durvalumab: an international, multicentre, retrospective cohort study
Vandeputte, H., Casadei-Gardini, A., Peeters, F., Rimini, M., Nichetti, F., Saborowski, A. L., Antonuzzo, L., Passeri, L., Satake, T., Vivaldi, C., et al. (2026) · ESMO Gastrointestinal Oncology · doi:10.1016/j.esmogo.2026.100335
Peripheral blood eosinophil count for predicting progression-free survival in non-small cell lung cancer: A retrospective cohort study
Chen, W., & Ding, G.-M. (2026) · Medicine · doi:10.1097/md.0000000000049256
Reprogramming the Melanoma Tumor Microenvironment: From Cellular Crosstalk to Cellular Immunotherapy
Jumaniyazova, E. D., Gantsova, E. A., Казарян, Г. Г., Charyeva, I., & Fatkhudinov, T. (2026) · Cancers · doi:10.3390/cancers18203325

Authors: Moreira, A., Leisgang, W., Schuler, G., & Heinzerling, L.
Affiliations: Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
ORCID: Moreira, Alvaro
Schuler, Gerold
Heinzerling, Lucie
Venue: Immunotherapy
Publisher: Informa UK Limited
Published: 2017-01-27
Volume: 9
Issue: 2
Pages: 115-121
ISSN: 1750-743X (ISSN-L)
1750-7448
DOI: 10.2217/imt-2016-0138
OpenAlex: W2581911737
Cited by: 147
References: 32
Citations by year: 2026: 7 · 2025: 17 · 2024: 9 · 2023: 18 · 2022: 28 · 2021: 22 · 2020: 24 · 2019: 9 · 2018: 7 · 2017: 6
FWCI: 5.55
Type: journal article
Language: en
Open access: closed
Locations: Immunotherapy (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Inflammatory Biomarkers in Disease Prognosis
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
Keywords: eosinophilia, eosinophil count, metastatic melanoma, prognostic factors, survival, immune checkpoint inhibitors, pembrolizumab, ipilimumab, blood eosinophils
MeSH terms: Adult, Aged, Aged, 80 and over, Animals, Cell Count, Eosinophils, Female, Humans, Immunotherapy, Male, Melanoma, Middle Aged, Neoplasm Metastasis, Prognosis, Biomarkers, Tumor, Survival Analysis, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Eosinophilic Count as a Biomarker for Prognosis of Melanoma Patients and Its Importance in The Response to Immunotherapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks